+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Ankylosing Spondylitis Market by Drug, Type of Molecule, Mechanism Of Action, Route Of Administration, Dosage Forms, End User - Global Forecast 2025-2030- Product Image
Ankylosing Spondylitis Market by Drug, Type of Molecule, Mechanism Of Action, Route Of Administration, Dosage Forms, End User - Global Forecast 2025-2030- Product Image
Sale

Ankylosing Spondylitis Market by Drug, Type of Molecule, Mechanism Of Action, Route Of Administration, Dosage Forms, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 195 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 5292911
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Ankylosing Spondylitis Market grew from USD 5.18 billion in 2023 to USD 5.60 billion in 2024. It is expected to continue growing at a CAGR of 8.31%, reaching USD 9.06 billion by 2030.

Ankylosing Spondylitis (AS) is a chronic inflammatory disease primarily affecting the spine and the sacroiliac joints, leading to pain and potentially severe functional disability. In terms of necessity, the market growth for AS treatments is driven by the aging population and increasing awareness coupled with advancements in diagnostic techniques. The application spans pharmaceuticals and biologics, focusing on anti-inflammatory drugs, TNF inhibitors, and IL-17 inhibitors. End-use scope is largely directed towards hospitals, clinics, and specialized rheumatology centers. The market's growth is significantly influenced by ongoing research identifying genetic markers for targeted treatment, innovations in biologic drugs, and an uptick in patient awareness leading to increased diagnostic rates. Latest opportunities lie in emerging economies where healthcare infrastructure is improving, alongside the potential development of biosimilars that promise cost-effective treatment options. Companies are recommended to invest in personalized medicine and leverage telemedicine platforms to enhance patient engagement and outcomes. Nonetheless, the market faces limitations such as the high cost of biologic therapies and potential side effects, which can deter treatment adherence. Additionally, the slow diagnosis rate remains a challenge, as symptoms tend to overlap with other conditions, leading to underdiagnosis or misdiagnosis. Key areas of innovation include biologic combination therapies and non-pharmacological interventions, such as advanced physiotherapy and digital health tools for monitoring disease progression. The market exhibits a competitive landscape with a strong emphasis on R&D for novel therapeutics. However, stringent regulatory policies can pose formidable hurdles in bringing new products to market. Overall, businesses should focus on collaborative research initiatives to bolster development pipelines and engage in strategic partnerships to expand geographical reach and improve access to care. Embracing these approaches will help capitalize on the evolving market dynamics while overcoming existing challenges.

Understanding Market Dynamics in the Ankylosing Spondylitis Market

The Ankylosing Spondylitis Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Increasing incidences of ankylosing spondylitis
    • Growing awareness about diagnostics and treatments for the disease
    • Rising number of orthopedic hospitals and diagnostic centers
  • Market Restraints
    • High cost of treatment and dearth of skilled surgeons and physiotherapists
  • Market Opportunities
    • Acceleration in research and development expenditure for the treatment of the spondylitis
    • The emergence of biologics for treating ankylosing spondylitis
  • Market Challenges
    • Concerns related to patent expiration of already approved drugs

Exploring Porter’s Five Forces for the Ankylosing Spondylitis Market

Porter’s Five Forces framework further strengthens the insights of the Ankylosing Spondylitis Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Ankylosing Spondylitis Market

External macro-environmental factors deeply influence the performance of the Ankylosing Spondylitis Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Ankylosing Spondylitis Market

The Ankylosing Spondylitis Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Ankylosing Spondylitis Market

The Ankylosing Spondylitis Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Ankylosing Spondylitis Market

The Ankylosing Spondylitis Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Ankylosing Spondylitis Market, highlighting leading vendors and their innovative profiles. These include Biothera Pharmaceuticals, Inc. by HiberCell, Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb, Celltrion Healthcare Co.,Ltd., Eisai Co., Ltd, Eli Lilly and Company, Hetero Drugs Limited, Novartis AG, Reliance Life Sciences, Samsung Bioepis Co., Ltd., Sandoz International GmbH, Sanofi-Aventis Groupe S.A., Shanghai Pharmaceuticals Holding Co., Ltd., Trinity Biotech PLC, and Xian Janssen Pharmaceutical Ltd.

Market Segmentation & Coverage

This research report categorizes the Ankylosing Spondylitis Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Drug
    • Cimzia
    • Cosentyx
    • Enbrel
    • Humira
    • Remicade
    • Simponi
  • Type of Molecule
    • Biologics
    • Small Molecules
  • Mechanism Of Action
    • Cyclooxygenase Inhibitors
    • Tumor Necrosis Factor Inhibitors
  • Route Of Administration
    • Oral
    • Parenteral
  • Dosage Forms
    • Liquid
    • Solid
  • End User
    • Clinics
    • Hospitals
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing incidences of ankylosing spondylitis
5.1.1.2. Growing awareness about diagnostics and treatments for the disease
5.1.1.3. Rising number of orthopedic hospitals and diagnostic centers
5.1.2. Restraints
5.1.2.1. High cost of treatment and dearth of skilled surgeons and physiotherapists
5.1.3. Opportunities
5.1.3.1. Acceleration in research and development expenditure for the treatment of the spondylitis
5.1.3.2. The emergence of biologics for treating ankylosing spondylitis
5.1.4. Challenges
5.1.4.1. Concerns related to patent expiration of already approved drugs
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Ankylosing Spondylitis Market, by Drug
6.1. Introduction
6.2. Cimzia
6.3. Cosentyx
6.4. Enbrel
6.5. Humira
6.6. Remicade
6.7. Simponi
7. Ankylosing Spondylitis Market, by Type of Molecule
7.1. Introduction
7.2. Biologics
7.3. Small Molecules
8. Ankylosing Spondylitis Market, by Mechanism Of Action
8.1. Introduction
8.2. Cyclooxygenase Inhibitors
8.3. Tumor Necrosis Factor Inhibitors
9. Ankylosing Spondylitis Market, by Route Of Administration
9.1. Introduction
9.2. Oral
9.3. Parenteral
10. Ankylosing Spondylitis Market, by Dosage Forms
10.1. Introduction
10.2. Liquid
10.3. Solid
11. Ankylosing Spondylitis Market, by End User
11.1. Introduction
11.2. Clinics
11.3. Hospitals
12. Americas Ankylosing Spondylitis Market
12.1. Introduction
12.2. Argentina
12.3. Brazil
12.4. Canada
12.5. Mexico
12.6. United States
13. Asia-Pacific Ankylosing Spondylitis Market
13.1. Introduction
13.2. Australia
13.3. China
13.4. India
13.5. Indonesia
13.6. Japan
13.7. Malaysia
13.8. Philippines
13.9. Singapore
13.10. South Korea
13.11. Taiwan
13.12. Thailand
13.13. Vietnam
14. Europe, Middle East & Africa Ankylosing Spondylitis Market
14.1. Introduction
14.2. Denmark
14.3. Egypt
14.4. Finland
14.5. France
14.6. Germany
14.7. Israel
14.8. Italy
14.9. Netherlands
14.10. Nigeria
14.11. Norway
14.12. Poland
14.13. Qatar
14.14. Russia
14.15. Saudi Arabia
14.16. South Africa
14.17. Spain
14.18. Sweden
14.19. Switzerland
14.20. Turkey
14.21. United Arab Emirates
14.22. United Kingdom
15. Competitive Landscape
15.1. Market Share Analysis, 2023
15.2. FPNV Positioning Matrix, 2023
15.3. Competitive Scenario Analysis
15.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. ANKYLOSING SPONDYLITIS MARKET RESEARCH PROCESS
FIGURE 2. ANKYLOSING SPONDYLITIS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2023 VS 2030 (%)
FIGURE 7. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2023 VS 2030 (%)
FIGURE 9. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2030 (%)
FIGURE 11. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 13. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2023 VS 2030 (%)
FIGURE 15. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
FIGURE 17. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 21. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 23. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 26. ANKYLOSING SPONDYLITIS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 27. ANKYLOSING SPONDYLITIS MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. ANKYLOSING SPONDYLITIS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. ANKYLOSING SPONDYLITIS MARKET DYNAMICS
TABLE 7. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY CIMZIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY COSENTYX, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ENBREL, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY HUMIRA, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY REMICADE, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SIMPONI, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY CYCLOOXYGENASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY LIQUID, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SOLID, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 30. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 31. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 36. ARGENTINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 37. ARGENTINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 38. ARGENTINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 39. ARGENTINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 40. ARGENTINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 41. ARGENTINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 42. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 43. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 44. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 45. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 46. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 47. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 48. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 49. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 50. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 51. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 52. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 53. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 54. MEXICO ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 55. MEXICO ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 56. MEXICO ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 57. MEXICO ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 58. MEXICO ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 59. MEXICO ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 67. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 68. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 69. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 70. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 71. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 72. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 73. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 74. AUSTRALIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 75. AUSTRALIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 76. AUSTRALIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 77. AUSTRALIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 78. AUSTRALIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 79. AUSTRALIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 80. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 81. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 82. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 83. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 84. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 85. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 86. INDIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 87. INDIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 88. INDIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 89. INDIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 90. INDIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 91. INDIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 92. INDONESIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 93. INDONESIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 94. INDONESIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 95. INDONESIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 96. INDONESIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 97. INDONESIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 98. JAPAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 99. JAPAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 100. JAPAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 101. JAPAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 102. JAPAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 103. JAPAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 104. MALAYSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 105. MALAYSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 106. MALAYSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 107. MALAYSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 108. MALAYSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 109. MALAYSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 110. PHILIPPINES ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 111. PHILIPPINES ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 112. PHILIPPINES ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 113. PHILIPPINES ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 114. PHILIPPINES ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 115. PHILIPPINES ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 116. SINGAPORE ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 117. SINGAPORE ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 118. SINGAPORE ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 119. SINGAPORE ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 120. SINGAPORE ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 121. SINGAPORE ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 122. SOUTH KOREA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 123. SOUTH KOREA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 124. SOUTH KOREA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 125. SOUTH KOREA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 126. SOUTH KOREA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 127. SOUTH KOREA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 128. TAIWAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 129. TAIWAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 130. TAIWAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 131. TAIWAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 132. TAIWAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 133. TAIWAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 134. THAILAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 135. THAILAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 136. THAILAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 137. THAILAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 138. THAILAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 139. THAILAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 140. VIETNAM ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 141. VIETNAM ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 142. VIETNAM ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 143. VIETNAM ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 144. VIETNAM ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 145. VIETNAM ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 153. DENMARK ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 154. DENMARK ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 155. DENMARK ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 156. DENMARK ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 157. DENMARK ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 158. DENMARK ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 159. EGYPT ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 160. EGYPT ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 161. EGYPT ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 162. EGYPT ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 163. EGYPT ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 164. EGYPT ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 165. FINLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 166. FINLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 167. FINLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 168. FINLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 169. FINLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 170. FINLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 171. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 172. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 173. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 174. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 175. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 176. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 177. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 178. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 179. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 180. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 181. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 182. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 183. ISRAEL ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 184. ISRAEL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 185. ISRAEL ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 186. ISRAEL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 187. ISRAEL ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 188. ISRAEL ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 189. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 190. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 191. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 192. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 193. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 194. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 195. NETHERLANDS ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 196. NETHERLANDS ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 197. NETHERLANDS ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 198. NETHERLANDS ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 199. NETHERLANDS ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 200. NETHERLANDS ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 201. NIGERIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 202. NIGERIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 203. NIGERIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 204. NIGERIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 205. NIGERIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 206. NIGERIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 207. NORWAY ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 208. NORWAY ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 209. NORWAY ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 210. NORWAY ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 211. NORWAY ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 212. NORWAY ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 213. POLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 214. POLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 215. POLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 216. POLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 217. POLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 218. POLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 219. QATAR ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 220. QATAR ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 221. QATAR ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 222. QATAR ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 223. QATAR ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 224. QATAR ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 225. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 226. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 227. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 228. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 229. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 230. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 231. SAUDI ARABIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 232. SAUDI ARABIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 233. SAUDI ARABIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 234. SAUDI ARABIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 235. SAUDI ARABIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 236. SAUDI ARABIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 237. SOUTH AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 238. SOUTH AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 239. SOUTH AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 240. SOUTH AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 241. SOUTH AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 242. SOUTH AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 243. SPAIN ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 244. SPAIN ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 245. SPAIN ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 246. SPAIN ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 247. SPAIN ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 248. SPAIN ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 249. SWEDEN ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 250. SWEDEN ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 251. SWEDEN ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 252. SWEDEN ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 253. SWEDEN ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 254. SWEDEN ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 255. SWITZERLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 256. SWITZERLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 257. SWITZERLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 258. SWITZERLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 259. SWITZERLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 260. SWITZERLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 261. TURKEY ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 262. TURKEY ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 263. TURKEY ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 264. TURKEY ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 265. TURKEY ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 266. TURKEY ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 267. UNITED ARAB EMIRATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 268. UNITED ARAB EMIRATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 269. UNITED ARAB EMIRATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 270. UNITED ARAB EMIRATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 271. UNITED ARAB EMIRATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 272. UNITED ARAB EMIRATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 273. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 274. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 275. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 276. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 277. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 278. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 279. ANKYLOSING SPONDYLITIS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 280. ANKYLOSING SPONDYLITIS MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Ankylosing Spondylitis Market, which are profiled in this report, include:
  • Biothera Pharmaceuticals, Inc. by HiberCell, Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb
  • Celltrion Healthcare Co.,Ltd.
  • Eisai Co., Ltd
  • Eli Lilly and Company
  • Hetero Drugs Limited
  • Novartis AG
  • Reliance Life Sciences
  • Samsung Bioepis Co., Ltd.
  • Sandoz International GmbH
  • Sanofi-Aventis Groupe S.A.
  • Shanghai Pharmaceuticals Holding Co., Ltd.
  • Trinity Biotech PLC
  • Xian Janssen Pharmaceutical Ltd

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages195
PublishedOctober 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 5.6 Billion
Forecasted Market Value ( USD ) by 2030 $ 9.06 Billion
Compound Annual Growth Rate8.3%
Regions CoveredGlobal
No. of Companies Mentioned15

Related Topics

Related Reports

Psoriasis Therapeutics Market by Molecule, Route of Administration, Dosage Forms, Mechanism of Action - Global Forecast 2025-2030 - Product Image

Psoriasis Therapeutics Market by Molecule, Route of Administration, Dosage Forms, Mechanism of Action - Global Forecast 2025-2030

  • Report
  • 181 Pages
  • Global
From
Pregabalin Market by Dosage Forms, Drug Class, Application, End-Users, Distribution Channel - Global Forecast 2025-2030 - Product Image

Pregabalin Market by Dosage Forms, Drug Class, Application, End-Users, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 184 Pages
  • Global
From
Oral Solid Dosage Forms (OSDF) and Pharma Excipients - Global Strategic Business Report - Product Image

Oral Solid Dosage Forms (OSDF) and Pharma Excipients - Global Strategic Business Report

  • Report
  • 196 Pages
  • Global
From
Fibrin Sealants Market By Dosage Forms, By Application, By End User: Global Opportunity Analysis and Industry Forecast, 2023-2032 - Product Image

Fibrin Sealants Market By Dosage Forms, By Application, By End User: Global Opportunity Analysis and Industry Forecast, 2023-2032

  • Report
  • 283 Pages
  • Global
From
Ankylosing Spondylitis Global Market Report 2024 - Product Image

Ankylosing Spondylitis Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From

About the Ankylosing Spondylitis Drug Market

The Ankylosing Spondylitis Drug market is a subset of the larger Musculoskeletal Disorders Drugs market. Ankylosing Spondylitis is a chronic inflammatory disorder that affects the spine and other joints, and is characterized by pain and stiffness. Ankylosing Spondylitis Drugs are used to reduce inflammation and pain, and to improve mobility. These drugs are typically administered orally or by injection, and may include biologics, non-steroidal anti-inflammatory drugs (NSAIDs), and corticosteroids. The Ankylosing Spondylitis Drug market is highly competitive, with a number of large pharmaceutical companies offering products. Some of the major players in the market include AbbVie, Amgen, Pfizer, Janssen, and Novartis. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.